published meta-analysis   sensitivity analysis   studies

mRNA vaccine in COVID-19 prophylaxis (children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed Covid-19, from 1st dosedetailed resultsC4591001 (Adolescents 12-25), 2021 0.08 [0.02; 0.34] 0.08[0.02; 0.34]C4591001 (Adolescents 12-25), 202110%2,260NAnot evaluable confirmed COVID (any severity)detailed resultsteenCOVE (P203) (Adolescents 12-17Y), 2021 0.07 [0.01; 0.46] 0.07[0.01; 0.46]teenCOVE (P203) (Adolescents 12-17Y), 202110%3,236NAnot evaluable symptomatic Covid-19detailed resultsC4591001 (Adolescents 12-25), 2021 0.03 [0.00; 0.50] 0.03[0.00; 0.50]C4591001 (Adolescents 12-25), 202110%1,983NAnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsC4591001 (Adolescents 12-25), 2021 0.25 [0.05; 1.13] 0.25[0.05; 1.13]C4591001 (Adolescents 12-25), 202110%2,239NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-04-27 21:10 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 330 - treatments: 806,758,826,755 - roots T: 290